BR112014023888A2 - método para a produção de um peptídeo recombinante e peptídeo resultante - Google Patents

método para a produção de um peptídeo recombinante e peptídeo resultante

Info

Publication number
BR112014023888A2
BR112014023888A2 BR112014023888-0A BR112014023888A BR112014023888A2 BR 112014023888 A2 BR112014023888 A2 BR 112014023888A2 BR 112014023888 A BR112014023888 A BR 112014023888A BR 112014023888 A2 BR112014023888 A2 BR 112014023888A2
Authority
BR
Brazil
Prior art keywords
pro
lys
gly
thr
arg
Prior art date
Application number
BR112014023888-0A
Other languages
English (en)
Other versions
BR112014023888B1 (pt
Inventor
Fedorovich Myasoedov Nikolay
Alexandrovna Andreeva Lyudmila
Viktorovich Golikov Dmitriy
Original Assignee
Ivix Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ivix Ltd. filed Critical Ivix Ltd.
Publication of BR112014023888A2 publication Critical patent/BR112014023888A2/pt
Publication of BR112014023888B1 publication Critical patent/BR112014023888B1/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04Linear peptides containing only normal peptide links
    • C07K7/06Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10Drugs for genital or sexual disorders; Contraceptives for impotence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08Tripeptides
    • C07K5/0802Tripeptides with the first amino acid being neutral
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10Tetrapeptides
    • C07K5/1002Tetrapeptides with the first amino acid being neutral
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10Tetrapeptides
    • C07K5/1002Tetrapeptides with the first amino acid being neutral
    • C07K5/1005Tetrapeptides with the first amino acid being neutral and aliphatic
    • C07K5/1013Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing O or S as heteroatoms, e.g. Cys, Ser
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08Peptides having 5 to 11 amino acids
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

resumo “método para a produção de um peptídeo recombinante e peptídeo resultante” a invenção refere-se à bioquímica e biotecnologia e destina-se à produção de peptídeos com atividade estimulante da função sexual de fórmula geral: a-thr-lys-pro-b-c-d-?, onde ? é 0, met, met(0), thr, ala, his, phe, lys, gly, b é 0, gly, asp, trp, gln, asn, tyr, pro, arg, c é 0, arg, phe, tyr, gly, his, pro, lys, d é 0, val, gly, tyr, trp, phe, his, ? é oh, ??h3, nh2, onde 0 é a ausência de um resíduo de aminoácido, sob a condição que, se a?0, então b e/ou c e/ou d?0, e se b?0, então c e/ou d?0, excluindo os peptídeos phe-thr-lys-pro-gly, thr-lys-pro-pro-arg, thr-lys-pro-arg-gly. a invenção também está direcionada para um método para produzir os peptídeos mencionados por métodos de engenharia genética.
BR112014023888-0A 2012-03-28 2013-05-28 Composições farmacêuticas compreendendo peptídeos recombinantes, usos de peptídeos recombinantes para estimular a função sexual e reprodutiva e para o tratamento curativo ou profilático de uma disfunção reprodutiva ou sexual e métodos não terapêuticos para estimular a função sexual ou reprodutiva BR112014023888B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
RU2012111965 2012-03-28
RU2012111965A RU2507212C3 (ru) 2012-03-28 2012-03-28 Способ получения рекомбинантного пептида и полученный пептид
PCT/RU2013/000433 WO2013151467A2 (ru) 2012-03-28 2013-05-28 Способ получения рекомбинантного пептида и полученный пептид

Publications (2)

Publication Number Publication Date
BR112014023888A2 true BR112014023888A2 (pt) 2018-05-29
BR112014023888B1 BR112014023888B1 (pt) 2021-12-07

Family

ID=49301137

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112014023888-0A BR112014023888B1 (pt) 2012-03-28 2013-05-28 Composições farmacêuticas compreendendo peptídeos recombinantes, usos de peptídeos recombinantes para estimular a função sexual e reprodutiva e para o tratamento curativo ou profilático de uma disfunção reprodutiva ou sexual e métodos não terapêuticos para estimular a função sexual ou reprodutiva

Country Status (12)

Country Link
US (2) US9409947B2 (pt)
EP (2) EP2876113B1 (pt)
BR (1) BR112014023888B1 (pt)
CA (1) CA2868820C (pt)
DK (1) DK2876113T3 (pt)
ES (1) ES2768300T3 (pt)
IL (1) IL234753B (pt)
IN (1) IN2014DN08984A (pt)
PL (1) PL2876113T3 (pt)
PT (1) PT2876113T (pt)
RU (1) RU2507212C3 (pt)
WO (1) WO2013151467A2 (pt)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2507212C3 (ru) * 2012-03-28 2022-05-04 Общество С Ограниченной Ответственностью "Айвикс" Способ получения рекомбинантного пептида и полученный пептид
RU2655763C2 (ru) 2016-10-24 2018-05-29 Общество С Ограниченной Ответственностью "Айвикс" Фармацевтическая композиция и способ лечения женских сексуальных дисфункций
RU2626002C1 (ru) * 2016-10-24 2017-07-21 Общество С Ограниченной Ответственностью "Айвикс" Новая группа пептидов для лечения женской сексуальной дисфункции
RU2709503C1 (ru) * 2019-05-23 2019-12-18 Акционерное общество "Инновационный научно-производственный центр "Пептоген" (АО "ИНПЦ "Пептоген") Применение пептида thr-lys-pro-arg-pro-gly-pro (селанк) для повышения резистентности организма к острой гипотермии

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3778426A (en) * 1970-12-16 1973-12-11 Research Corp Therapeutically useful polypeptides
RU1124544C (ru) * 1983-06-30 1995-01-09 Институт молекулярной генетики РАН Гептапептид, обладающий свойствами психостимулятора пролонгированного действия с иммунотропной активность
RU2058791C1 (ru) 1989-01-11 1996-04-27 Государственное предприятие "Элер-микро" Стимулятор репродуктивной способности у теплокровных животных
US5872100A (en) 1990-05-11 1999-02-16 Deghenghi; Romano Peptides containing D-2-Alkyl-Tryptophan
DE69429768T2 (de) 1993-04-05 2002-09-19 Competitive Tech Inc Diagnose und behandlung von erektilen funktionsstörungen
US5932548A (en) 1998-06-03 1999-08-03 Deghenghi; Romano Lysine containing peptides for treatment of heart disease
RU2155065C1 (ru) 1999-04-23 2000-08-27 Институт молекулярной генетики РАН Анксиолитическое средство и фармацевтическая композиция анксиолитического действия
US6211156B1 (en) 1999-11-10 2001-04-03 Asta Medica A.G. Peptides for treatment of erectile dysfunction
RU2252779C1 (ru) 2003-09-23 2005-05-27 Институт Молекулярной Генетики Российской Академии Наук (Имг Ран) Способ профилактики и лечения язв желудочно-кишечного тракта
RU2290195C1 (ru) 2005-04-21 2006-12-27 Институт Молекулярной Генетики Российской Академии Наук (Имг Ран) Средство с антикоагулянтной, антитромбоцитарной, антитромботической, фибриндеполимеризационной и фибринолитической активностями
CN101302246B (zh) 2007-05-09 2011-05-11 中国人民解放军军事医学科学院毒物药物研究所 黑色素皮质激素受体七肽类激动剂及其制备方法和用途
KR20100075439A (ko) 2007-09-11 2010-07-02 몬도바이오테크 래보래토리즈 아게 치료제로서의 감마 1 msh 단독 또는 펜타가스트린과의 배합물
US7618801B2 (en) 2007-10-30 2009-11-17 Danison US Inc. Streptomyces protease
RU2411249C2 (ru) * 2008-12-11 2011-02-10 Учреждение Российской академии наук Институт молекулярной генетики РАН (ИМГ РАН) Средство против вирусов: энцефаломиокардита, гриппа а, простого герпеса 2
RU2404793C1 (ru) * 2009-06-04 2010-11-27 Общество с ограниченной ответственностью Био Пептид Стимулятор половой, сексуальной и репродуктивной функции
EA200900804A1 (ru) * 2009-06-08 2010-08-30 Общество С Ограниченной Ответственностью "Витанта" Средство, активирующее половую функцию
RU2507212C3 (ru) * 2012-03-28 2022-05-04 Общество С Ограниченной Ответственностью "Айвикс" Способ получения рекомбинантного пептида и полученный пептид

Also Published As

Publication number Publication date
WO2013151467A2 (ru) 2013-10-10
CA2868820C (en) 2021-09-21
CA2868820A1 (en) 2013-10-10
DK2876113T3 (da) 2020-02-03
EP3650457B1 (en) 2021-03-17
EP2876113A2 (en) 2015-05-27
BR112014023888B1 (pt) 2021-12-07
EP2876113B1 (en) 2019-11-06
EP3650457A1 (en) 2020-05-13
US9409947B2 (en) 2016-08-09
US20150111837A1 (en) 2015-04-23
EP2876113A4 (en) 2017-03-01
US20170158735A1 (en) 2017-06-08
PL2876113T3 (pl) 2020-06-15
ES2768300T3 (es) 2020-06-22
IL234753B (en) 2018-11-29
IN2014DN08984A (pt) 2015-05-22
RU2012111965A (ru) 2013-10-10
RU2507212C2 (ru) 2014-02-20
RU2507212C3 (ru) 2022-05-04
PT2876113T (pt) 2020-02-03
WO2013151467A3 (ru) 2014-01-09

Similar Documents

Publication Publication Date Title
EA202090090A1 (ru) Включение неприродных нуклеотидов и способы с ними
PE20240015A1 (es) Proteinas de fusion gdf15 y usos de estas
MX2013013913A (es) Polipeptidos.
IN2014CN04498A (pt)
BR112016014810A2 (pt) Antagonistas de fcrn e métodos de uso
BR112017015833A2 (pt) compostos anti-senescência e usos dos mesmos
BR112012020953A2 (pt) produto, uso do mesmo, metodo para prevencao e/ou tratamento de fibrose corneana ou opacidade corneana e composicao farmaceutica oftalmica
BR112016029413A2 (pt) utilização de inibidores peptídicos permeáveis às células da via de transdução do sinal da jnk para o tratamento de várias doenças
EA201990071A1 (ru) Композиция пептидной вакцины
CU20120116A7 (es) Polipéptidos que se enlazan a dr5 humana con efectos agonistas, que comprenden uno o más monómeros de un único dominio variable, utiles en el tratamiento de enfermedades y trastornos asociados con dr5
EP3939606A3 (en) Improved methods and compounds for eliminating immune responses to therapeutic agents
MX2017014730A (es) Muteinas de lipocalina 2 humana con afinidad por glipicano-3 (gpc3).
BR112018076215A2 (pt) partículas e composições de nicotina
BR112018072034A2 (pt) compostos mic-1 e usos dos mesmos
BR112014023888A2 (pt) método para a produção de um peptídeo recombinante e peptídeo resultante
MX350445B (es) Analogos del factor b del complemento y sus usos.
EA201490790A1 (ru) Пептидные конъюгаты агониста рецептора гастрина и глюкагон подобного пептида 1
AR102445A1 (es) COMPOSICIONES Y MÉTODOS RELACIONADOS CON b-GLUCOSIDASA
BR112015018335A2 (pt) Composições nutritivas contendo um componente peptídico com propriedades anti-inflamatórias e usos das mesmas
WO2016131000A3 (en) Tolerance therapeutic for treating polypeptide induced allergy
CL2017000200A1 (es) Célula huésped mejorada para producir proteinas
BR112014028130A2 (pt) Sal de cloridrato de um peptídeo, composição farmacêutica, uso de um sal de cloridrato, uso de uma composição farmacêutica, e, método para evitar ou tratar alergia a gatos
BR112018072968A2 (pt) peptídeos monolipidados resistentes às proteases
CO2017013404A2 (es) Variantes de il-37
BR112017014737A2 (pt) formulação de peptídeos inibidores de mk2

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NAO 10196/2001, QUE MODIFICOU A LEI NAO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUAANCIA PRA VIA DA ANVISA. CONSIDERANDO A APROVAA AO DOS TERMOS DO PARECER NAO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NAO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDAANCIAS CABA-VEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B15I Others concerning applications: loss of priority

Free format text: PERDA DA PRIORIDADE RU2012111965 DE 28/03/2012 REIVINDICADA NO PCT/RU2013/000433, CONFORME AS DISPOSICOES PREVISTAS NA LEI 9.279 DE 14/05/1996 (LPI) ART. 16 7O, DECRETO NO. 635 DE 21/08/1992 E CONVENCAO DA UNIAO DE PARIS (REVISTA EM ESTOCOLMO 14/07/1967), ART. 4O, ALINEA C, ITEM 1. ESTA PERDA SE DEU PELO FATO DO BRASIL NAO ACEITAR RESTAURACAO DE PRIORIDADE (RESERVA DO BRASIL DE ACORDO COM A REGRA 49TER.2 ALINEA (H) C/C REGRA 26 BIS.3 ALINEA (J) DO REGULAMENTO DE EXECUCAO DO PCT), RESTAURACAO ESTA QUE FOI CONCEDIDA PELA OMPI, JA QUE O PRAZO PARA O DEPOSITO INTERNACIONAL COM REIVINDICACAO DE PRIORIDADE ULTRAPASSOU OS 12 MESES.

B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 28/05/2013, OBSERVADAS AS CONDICOES LEGAIS.

B25A Requested transfer of rights approved

Owner name: OVB (IRELAND) LIMITED (IE)